MUMBAI, India and BALTIMORE, Md. — Pharma major Lupin announced that it has received approval for its budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules from the United States Food and Drug Administration to market a generic version of AstraZeneca Pharmaceuticals LP’s (AstraZeneca) Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL.

Lupin’s budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules is the generic version of AstraZeneca’s Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL. It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.